公开(公告)号：US06727401B1

公开(公告)日：2004-04-27

申请号：US09022504

申请日：1998-02-12

Applicant: Srinivasan Venkateshwaran ,  Danyi Quan

Inventor： Srinivasan Venkateshwaran ,  Danyi Quan

IPC: A61F1300

CPC classification number: A61K9/7061 ,  A61F13/105 ,  A61K8/4946 ,  A61Q3/00

Abstract: A device for treating antifungal infections of toenails and fingernails is made up of an occlusive backing layer and a pressure sensitive adhesive matrix layer in which is uniformly dispersed an effective amount of an antifungal agent and, optionally, a chemical enhancer. The matrix layer has a first surface adhering to the backing layer and a second surface adapted to be in diffusional contact with the infected nail and surrounding skin area. The device is configured, when applied, to cover and adhere to the nail and surrounding skin areas for an extended period of time without causing irritation to the skin or inhibiting normal physical activity while providing a continuous delivery of antifungal agent to the infected area.

Abstract translation: 用于治疗脚趾甲和指甲的真菌感染的装置由闭塞背衬层和压敏粘合剂基质层组成，其中均匀分散有效量的抗真菌剂和任选的化学增强剂。 基质层具有粘附到背衬层的第一表面和适于与受感染的指甲和周围皮肤区域扩散接触的第二表面。 该装置在施用时被配置为在延长的时间段内覆盖并粘附到指甲和周围皮肤区域，而不会对皮肤产生刺激或抑制正常的身体活动，同时提供抗真菌剂到感染区域的连续递送。

公开(公告)号：US06180133B2

公开(公告)日：2001-01-30

申请号：US09198734

申请日：1998-11-24

Applicant: Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K970

CPC classification number: A61Q19/08 ,  A61F9/04 ,  A61F13/122 ,  A61F2013/00374 ,  A61F2013/00497 ,  A61F2013/00906 ,  A61K8/0208 ,  A61K8/676 ,  A61K8/678 ,  A61K2800/522 ,  Y10S514/844 ,  Y10S514/848 ,  Y10S514/975

Abstract: An anti-wrinkle skin treating composition comprises a pressure sensitive matrix patch having dissolved in the adhesive a mixture of antioxidants in the form of a Vitamins C ester and Vitamin E. Also preferably dissolved in the adhesive are glycerine and a polydiorganosiloxane adhesion-adjusting agent. Optionally dissolved in the adhesive is also one or more members selected from the group consisting of moisturizing agents, skin collagen synthesis promoting agents and exfoliating agents. When applied to a wrinkled skin area the composition acts to diminish fine wrinkles and improves the overall thickness, elasticity, firmness and smoothness of the skin. The modified adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin.

Abstract translation: 抗皱皮肤处理组合物包含在维生素C酯和维生素E形式的溶解在粘合剂中的抗氧化剂混合物的压敏基质贴片。还优选溶解在粘合剂中的是甘油和聚二有机硅氧烷粘合调节剂。 任选地溶解在粘合剂中也是选自保湿剂，皮肤胶原合成促进剂和去角质剂的一种或多种。 当应用于起皱的皮肤区域时，组合物起减少细小皱纹的作用，并提高皮肤的整体厚度，弹性，坚固度和平滑度。 贴剂的改性粘合剂性能足以将贴片保持在皮肤上适合推荐的治疗期，同时允许容易地去除贴片而不引起皮肤刺激或在皮肤上留下粘合剂残留物。

公开(公告)号：US06730318B2

公开(公告)日：2004-05-04

申请号：US09924564

申请日：2001-08-08

Applicant: Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61F1302

CPC classification number: A61K8/891 ,  A61F9/04 ,  A61F13/122 ,  A61F2013/00374 ,  A61F2013/00497 ,  A61F2013/00906 ,  A61K8/0208 ,  A61K8/676 ,  A61K8/678 ,  A61K9/7053 ,  A61K9/7061 ,  A61Q19/00 ,  A61Q19/08

Abstract: The adhesive capability of matrix-type transdermal devices for the delivery of drugs, cosmetics, emollients and the like is altered by incorporating into the pressure-sensitive adhesive an effective amount of a polydiorganosiloxane polymer fluid adhesion adjusting agent. The properties of the pressure-sensitive adhesive are modified to enable a matrix-type patch to adhere temporarily to the skin for a period sufficient to accomplish its desired delivery purpose and then be removed without causing skin damage or irritation and without leaving substantial adhesive residue on the skin. Polydimethylsiloxanes (dimethicones) are preferred adhesion adjusting agents and acrylic-based polymers are preferred pressure-sensitive adhesives. Matrix-type patches containing anti-wrinkle agents formulated with dimethicones in the adhesive for application to areas on the face and particularly around the eyes are especially useful.

Abstract translation: 用于递送药物，化妆品，润肤剂等的基质型透皮装置的粘合能力通过将有效量的聚二有机硅氧烷聚合物流体粘附调节剂并入压敏粘合剂而改变。 修改压敏粘合剂的性能以使基质型贴片能够临时粘附到皮肤上足够长的时间以实现其期望的递送目的，然后在不引起皮肤损伤或刺激的情况下被除去并且不会留下大量的粘合剂残留物 皮。 聚二甲基硅氧烷（二甲基硅氧烷）是优选的粘合调节剂，丙烯酸类聚合物是优选的压敏粘合剂。 在粘合剂中用二甲硅油配制的抗皱剂的基质型贴剂适用于脸部和特别是眼睛周围的区域是特别有用的。

公开(公告)号：US5601839A

公开(公告)日：1997-02-11

申请号：US429757

申请日：1995-04-26

Applicant: Danyi Quan ,  Ninad A. Deshpanday ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Danyi Quan ,  Ninad A. Deshpanday ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K9/00 ,  A61K9/70 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/216 ,  A61K31/404 ,  A61K31/4458 ,  A61K31/46 ,  A61K31/485 ,  A61K31/5415 ,  A61K31/55 ,  A61K47/10 ,  A61K47/14 ,  A61K47/30 ,  A61K47/32 ,  A61P9/00 ,  A61P9/06 ,  A61P21/02 ,  A61P23/02 ,  A61P25/04 ,  A61P25/24 ,  A61P25/26 ,  A61P27/02 ,  A61F13/02

CPC classification number: A61K9/7053 ,  A61K47/14 ,  A61K9/0014 ,  A61K9/7061 ,  A61K9/7069 ,  Y10S514/946

Abstract: A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consisting essentially of triacetin, and a polymer later preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.

Abstract translation: 描述了用于增强基础药物透皮渗透的组合物和方法。 所述组合物包含基质贴片，其包含有效量的碱性药物，优选具有约8.0或更大的pKa，有效量的基本上由三醋精组成的渗透促进剂，以及稍后优选包含压敏粘合剂的聚合物。 优选的碱性药物是奥昔布宁及其酸加成盐。 用于增强透皮渗透的方法包括将基质片施加到选定的皮肤区域。

公开(公告)号：US5834010A

公开(公告)日：1998-11-10

申请号：US775367

申请日：1997-01-03

Applicant: Danyi Quan ,  Ninad A. Deshpanday ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Danyi Quan ,  Ninad A. Deshpanday ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K9/00 ,  A61K9/70 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/216 ,  A61K31/404 ,  A61K31/4458 ,  A61K31/46 ,  A61K31/485 ,  A61K31/5415 ,  A61K31/55 ,  A61K47/10 ,  A61K47/14 ,  A61K47/30 ,  A61K47/32 ,  A61P9/00 ,  A61P9/06 ,  A61P21/02 ,  A61P23/02 ,  A61P25/04 ,  A61P25/24 ,  A61P25/26 ,  A61P27/02 ,  A61F13/02

CPC classification number: A61K9/7053 ,  A61K47/14 ,  A61K9/0014 ,  A61K9/7061 ,  A61K9/7069 ,  Y10S514/946

Abstract: A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of a penetration enhancer consisting essentially of triacetin, and a polymer layer preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.

Abstract translation: 描述了用于增强基础药物透皮渗透的组合物和方法。 组合物包含基质片，其包含有效量的碱性药物，优选具有约8.0或更大的pKa，有效量的基本上由甘油三乙酸酯组成的渗透促进剂和优选包含压敏粘合剂的聚合物层。 优选的碱性药物是奥昔布宁及其酸加成盐。 用于增强透皮渗透的方法包括将基质片施加到选定的皮肤区域。

公开(公告)号：US11304960B2

公开(公告)日：2022-04-19

申请号：US12350930

申请日：2009-01-08

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/569 ,  A61K9/48 ,  A61K31/568 ,  A61K9/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

公开(公告)号：US20150038475A1

公开(公告)日：2015-02-05

申请号：US14500438

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/20 ,  A61K47/10 ,  A61K47/36 ,  A61K31/568

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

Abstract translation: 本公开涉及含有十一酸睾酮的药物组合物和口服剂型，以及相关的治疗方法。 在一个实施方案中，口服剂型可以包括治疗有效量的十一酸睾酮和药学上可接受的载体。 可以配制剂型，使得当使用USP II型装置在1000mL的8重量％Triton X-100在水中在37℃和100rpm下测量时，口服剂型释放至少20％以上的睾酮 十一酸十一酸酯比不含药学上可接受的载体的含有口服剂型的等效剂量十一酸睾酮。

公开(公告)号：US20150018324A1

公开(公告)日：2015-01-15

申请号：US14500498

申请日：2014-09-29

Applicant: Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Basawaraj Chickmath ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K9/28 ,  A61K47/38 ,  A61K47/10 ,  A61K9/20 ,  A61K31/568 ,  A61K47/36

CPC classification number: A61K9/2031 ,  A61K9/14 ,  A61K9/146 ,  A61K9/148 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/36 ,  A61K47/38 ,  A61K47/40

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

公开(公告)号：US20120322780A1

公开(公告)日：2012-12-20

申请号：US13592258

申请日：2012-08-22

Applicant: Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

Inventor： Chandrashekar Giliyar ,  Nachiappan Chidambaram ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

IPC: A61K31/568 ,  A61P5/26

CPC classification number: A61K31/569 ,  A61K9/0053 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/568 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.

Abstract translation: 本文提供了适用于向个体提供治疗有效量的至少一种类固醇的含甾族化合物的组合物。 本文还提供包含适于在一段时间内提供治疗有效和安全量的睾酮的睾酮和/或睾酮衍生物的组合物。 还提供了通过给予本文所述的个体组合物来治疗个体中的和/或睾酮缺乏症的方法。

公开(公告)号：US5780050A

公开(公告)日：1998-07-14

申请号：US504430

申请日：1995-07-20

Applicant: Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

Inventor： Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

IPC: A61K9/70 ,  A61K31/565 ,  A61K31/57 ,  A61K47/04 ,  A61K47/10 ,  A61K47/14 ,  A61K47/16 ,  A61K47/20 ,  A61K47/30 ,  A61K47/32 ,  A61K47/44 ,  A61P5/24 ,  A61P5/38 ,  A61F13/00

CPC classification number: A61K9/7061 ,  A61K31/568 ,  A61K31/569 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575

Abstract: A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.

Abstract translation: 描述了一种用于经皮药物递送含有3-酮-4-烯官能团的类固醇药物的稳定补片装置，其中补片包含有效量的类固醇药物和不含酸官能团的载体。 该装置可以进一步含有添加剂如渗透促进剂或赋形剂，只要这些添加剂也不含酸官能团。 该装置可以是矩阵补丁或液体储存器补丁。 在基质贴剂中，载体是与类固醇药物紧密混合的生物相容的聚合物粘合剂。 粘合剂优选为丙烯酸类聚合物或共聚物。 在液体储存贴片中，载体是含有较薄或增稠剂的受控粘度组合物。 优选的类固醇药物包括某些皮质类固醇和性激素，如孕激素和雄激素。 还公开了在透皮贴剂储存期间稳定这种类固醇药物的方法。